Weekly round-up: Alys breaks new ground with first Phase 2a trial of a genetic medicine program in dermatology
Alys Pharmaceuticals, Inc., an immuno-dermatology focused company, on Tuesday announced that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug (IND) / Clinical Trial Application (CTA) for the study of ALY-101 in patients suffering from Alopecia Areata (AA).
Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion
Akribion Therapeutics, the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, on Tuesday announced its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based on Akribion’s proprietary G-dase® E nucleases.
Liva Healthcare acquires Momenta, and secures funding from new and existing investors to drive growth
Liva Healthcare, a digital health technology platform with human-led therapeutic intervention programmes that deliver best-in-class outcomes for lifestyle-related chronic diseases, on Wednesday announced that it has acquired UK-based Discover Momenta, including subsidiary Momenta Newcastle, for an undisclosed sum. The acquisition of Momenta is part of Liva’s growth strategy as it emerges as a major international provider of evidence-based therapeutic lifestyle interventions.
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, on Thursday announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).
Optimum at Hevolution Global HealthSpan Summit 2025
Thousands attend Hevolution’s ground breaking Healthspan Summit in Riyadh.
Our CEO Mary Clark joined more than 3k attendees and 150 speakers in Riyadh, Kingdom of Saudi Arabia, this week for the Hevolution Foundation Global Healthspan Summit 2025. With such high-quality speakers and fantastic sessions covering important topics across the whole ecosystem, Riyadh has truly become the home of the healthspan revolution.
Optimum Perspectives
Want to know how bioengineered spider silk protein fibres can be applied within the textile, biomedical, and automobile industries?
In the latest episode of Optimum Perspectives, hear from Benoit Cugnet, Head of Fiber Business Unit at AMSilk, on how this German biotech is changing the face of advanced materials.
Listen to the full episode here!
Optimum’s hot topic
Read Optimum’s hottest take of the week here.
Industry events
Optimum’s Hollie Vile had a busy week, speaking at One Nucleus’ BioWednesday in Stevenage, before heading off to EQT’s BioCapital in Amsterdam!
If you would like to catch up with the Optimum Team, we will be attending BioEurope Spring in Milan next month. Please reach out if you would like to connect with CEO Mary Clark and Account Director Hana Malik there.
That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe on LinkedIn today so you never miss an edition.
